Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, briefly explains the importance of measurable residual disease (MRD) evaluation in multiple myeloma, and the benefit of integrating MRD monitoring in clinical practice to offer patients the best treatment options. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.